FDA Approves Xeomin (incobotulinumtoxinA) for Adult Patients with Sialorrhea (Excessive Drooling)

RALEIGH, N.C., July 3, 2018 -- Merz North America announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of chronic...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news